Cellectis (CLLS) Share-based Compensation (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.09% |
| Dec 31, 2025 | 100.14% |
| Sep 30, 2025 | -49,436.18% |
| Jun 30, 2025 | -431.35% |
| Mar 31, 2025 | -99.96% |
| Dec 31, 2024 | 503.92% |
| Sep 30, 2024 | 31.81% |
| Jun 30, 2024 | -93,673.84% |
| Mar 31, 2024 | -80.81% |
| Dec 31, 2023 | -99.83% |
| Sep 30, 2023 | 261.18% |
| Jun 30, 2023 | -101,704.94% |
| Mar 31, 2023 | 318.60% |
| Dec 31, 2022 | -96.12% |
| Sep 30, 2022 | 250.28% |
| Jun 30, 2022 | -386.83% |
| Mar 31, 2022 | 19.81% |
| Dec 31, 2021 | -65.11% |
| Sep 30, 2021 | 38.85% |
| Jun 30, 2021 | 13,200.00% |
| Mar 31, 2021 | 101.08% |
| Dec 31, 2020 | -182.22% |
| Sep 30, 2020 | -27.31% |
| Jun 30, 2020 | -2.62% |
| Mar 31, 2020 | -32.67% |
| Dec 31, 2019 | -11.08% |
| Sep 30, 2019 | 18.74% |
| Jun 30, 2019 | 31.93% |
| Mar 31, 2019 | -36.78% |
| Dec 31, 2018 | -1.07% |
| Sep 30, 2018 | -9.59% |
| Jun 30, 2018 | -25.07% |
| Mar 31, 2018 | 4.70% |
| Dec 31, 2017 | -10.86% |
| Sep 30, 2017 | -54.12% |
| Jun 30, 2017 | 106.13% |
| Mar 31, 2017 | -3.35% |
| Dec 31, 2016 | 4.18% |
| Sep 30, 2016 | -16.78% |
| Jun 30, 2016 | 9.83% |
| Mar 31, 2016 | 6.94% |
| Dec 31, 2015 | 31.43% |
| Sep 30, 2015 | 32.72% |
| Jun 30, 2015 | 735.73% |